Melagyn®

With tea tree oil

Effective intimate hygiene

Melagyn®
Effective intimate hygiene

Aetiology of vulvovaginal infections Gel, Spray and Wipes

90% of all cases of vulvovaginitis are infectious: 1

• Candidiasis (Candida spp.)
75% of all women have developed 1 episode of candidiasis 2
50% of recurrences (negative culture ≠ fungal eradication)
• Bacterial vaginitis (Gardnerella vaginalis)
• Parasitosis (Trichomonas vaginalis)
Candida albicans
• Viriasis (Herpes simplex)

When should Melagyn® be recommended?

• Daily as prevention against the risk of infections at different stages in women’s life

Childbearing age 3-5 Pregnancy 3-5 Menopause 6 Elderly women 7

Menstruation, Hormonal changes, Strogen deficiency, Incontinence,
contraceptive use greater glycogen vaginal dryness polymedication,
production, episiotomy vaginal atrophy

Also in specific situations such us cystitis, antibiotic therapy, diabetes, sexual intercouse, inmune suppression,
hypothyroidism, anaemia

•C
 oadjuvant use with antifungal and antibiotic treatment symptomatology
%

-74%
relieves discomfort and reduces the risk of recurrence8-9 reduction -67% -64%

Extracted from 8
Itch Erythema Injuries N=488
scratch
Melaleuca alternifolia study in dermatological and gynecological
Melagyn® protects in a natural way and prevents infecctions infections from micotic and bacterial origin
Melagyn®
Effective intimate hygiene

One intimate gel for all women and types of infection

• It contains tea tree oil (Melaleuca alternifolia 0.6%) with unique properties endorsed by more than
40 studies:

• Antifungal10 → against Candida albicans

- Fungistatic MIC 0,25%
- Fungicide MFC 0,25 to 0,5%
CMI: Minimum inhibitory concentration - CMF: Minimum fungicidal concentration

• Antibacterial11 → against Gardnerella vaginalis (MIC 0,06%),

respecting lactobacillus from normal microbiota

• Antiprotozoal12 → against Trichomonas vaginalis

• Antiviral13 → against Herpes simplex

• Topical anti-inflammatory14

• Antipruritic14

•p
 H 8,5: Screen effect. Prevents entry of Candida in the vagina that may occur during sexual intercourse
or innacurate hygiene

1 14
2 3 12 13
4 4.5 5 5.5 6 7 8 9 10 11
acidic basic
pH vaginal vulvar neutral pH
pH pH

pH 8.5
Screen effect.
Fungal proliferation 15
Hinders fungal Disappearance of flora
proliferation

• Melagyn®contains gentle tensoactive agents. Suitable for sensitive skins

 Properties of main ingredients in intimate gels
Antifungal Antibacterial Antiviral Anti-inflammatory Antipruritic

Tea tree
Burdock

Lactic acid
Scientific evidence of tea tree shown in + 40 studies

The most comprehensive range

Melagyn® Gel Intimate hygiene coadjuvant to

Melaleuca vulvovaginitis treatment
alternifolia
Regular intimate hygiene for
0.6%
the prevention of recurrences

Melagyn® Spray
Melaleuca
Instant relief of intimate itching
alternifolia and burning
0.6%

Melagyn® Wipes Melaleuca

alternifolia Cleanliness and freshness with no need to rinse
0.25%

Also indicated in haemorrhoid care

1. Carreras J. Aspectos actuales en la evaluacion y el tratamiento de las vulvovaginitis. Med Integral 2002;40:185-9. 2. Wilson C. Recurrent vulvovaginitis candidiasis; an overview of traditional and alternative
therapies. Adv Nurse Pract 2005;13(5):24-9. 3. Barrenetxea Ziarrusta G. Vulvovaginitis candidiasica. Rev Iberoam Micol. 2002;19-22-24. 4. Fihn SD. Acute Uncomplicated Urinary Tract Infection in women. N Engl
J Med. 2003;349(3):259-66. 5. Jankovic´ S, Bojovic´ D, Vukadinovic´ D, Daglar E, Jankovic´ M, Laudanovic´ D, Lukic´ V, Miskovic´ V, Potpara Z, Projovic´ I, Cokanovic´ V, Petrovic´ N, Folic´ M, Savic´ V. Risk factors
for recurrent vulvovaginal candidiasis. Vojnosanit Pregl. 2010;67(10):819-24. 6. Grupo de trabajo de menopausia y postmenopausia. Guia de practica clinica sobre la menopausia y postmenopausia. Barcelona:
Sociedad Espanola de Ginecologia y Obstetricia, Asociacion Espanola para el Estudio de la Menopausia, Sociedad Espanola de Medicina de Familia y Comunitaria y Centro Cochrane Iberoamericano; 2004.
7. Moore EE at al. Urinary incontinence and urinary tract infection: temporal relationships in postmenopausal women. Obstet Gynecol. 2008; 111(2 Pt 1): 317-23. Nabhan A. Vulvovaginal Candidiasis. ASJOG.
2006;3:73-79. 8. Baspeyras M. D’une hygiene locale adjuvante lors d’affections mycosiques ou bacteriennes. Phytotherapy 1995; 43:32–5. 9. Menoguía Salud vaginal. Asociación Española para el Estudio de
la Menopausia (AEEM), Marzo 2014. 10. Mondello F, De Bernardis F, Girolamo A, Cassone A, Salvatore G. In vivo activity of terpinen-4-ol, the main bioactive component of Melaleuca alternifolia Cheel (tea tree) oil
against azole-susceptible and -resistant human pathogenic Candida species. BMC Infect Dis. 2006;6:158. 11. Hammer KA, Carson CF, Riley TV. In vitro susceptibilities of lactobacilli and organisms associated with
bacterial vaginosis to Melaleuca alternifolia (tea tree) oil. Antimicrob Agents Chemother 1999;43:196. 12. Pena EF. Melaleuca alternifolia oil. Its use for trichomonal vaginitis and other vaginal infections. Obstet
Gynecol 1962;19:793-5. 13. Astani A, Reichling J, Schnitzler P. Comparative study on the antiviral activity of selected monoterpenes derived from essential oils. Pythother Res 2009; 24(5):673-9. 14. Carson CF,
Hammer KA, Riley TV. Melaleuca alternifolia (tea tree) oil: a review of antimicrobial and other medicinal properties. Clin Microbiol Rev 2006;19:50-62.

www.gynea.com